Packaging specialist Gerresheimer is continuing to restructure its portfolio. Following a strategic review, the company has decided to separate its molded glass business from the rest of the group and initiate a sale process. The aim is to establish the newly created “Molded Glass Powerhouse” as an independent unit.
Gerresheimer forms global molded glass powerhouse
The decision follows the integration of Bormioli Pharma in 2024, which created a global supplier of glass packaging with eight production sites in Europe, the US, and India. The combined molded glass business generated revenue of around €735 million in the financial year 2024. It employs around 3,700 people and offers Type I, II, and III glass products for the pharmaceutical industry, as well as for the cosmetics, food, and beverage industries.
Gerresheimer is focusing on the pharmaceutical industry and biotech sector
With the spin-off and planned sale of the molded glass segment, Gerresheimer is pursuing its goal of consistently positioning itself as a system and solution provider for the pharmaceutical and biotech industries. The focus is on pharmaceutical primary packaging, closure solutions, accessories, and dosing systems. The company's portfolio is specifically geared toward biopharmaceutical applications and high-value solutions made of plastic. The acquisition of Bormioli Pharma has further strengthened this strategic focus and opened up new opportunities for system integration.
Investments in modern production technology in Lohr am Main
A key project within the Molded Glass division is the expansion of the Lohr am Main site. Over the past two years, around €100 million has been invested in modern, energy-efficient production technologies there.
Outlook: Gerresheimer to announce further details in October
Gerresheimer plans to announce further details of the sale process at its Capital Market Day on October 15, 2025. The planned sale is part of a comprehensive transformation aimed at further expanding the company's market position in the pharmaceutical and biotechnology sectors.
